Viewing
|Articles|December 17, 2008

Novel conjunctivitis drug recommended by FDA

Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.

Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.

Besifloxacin, a broad-spectrum fluoroquinolone anti-microbial agent, works by inhibiting inflammation in THP-1 monocytes.

The FDA recommendation is a step towards final approval; if approved, Bausch & Lomb aims to bring besifloxacin to the market next year.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME